Basler Kantonalbank (SWX:BSKP) is attracting a fresh round of investor curiosity, largely because its latest gains have put it on the radar for those debating whether to make a move. The bank’s share price has shown an uptick in the past month, giving both long-term holders and new watchers a reason to reexamine what is driving momentum behind Switzerland’s regional banking fixture. While there has not been a headline-grabbing event, the recent action has nonetheless prompted questions about...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.